Canagliflozin
- PDF / 170,506 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 84 Downloads / 225 Views
1 S
Canagliflozin Superior mesenteric artery syndrome, euglycemic ketoacidosis and rapid body weight loss: case report
A 58-year-old woman developed superior mesenteric artery (SMA) syndrome, euglycemic ketoacidosis and excessive loss of body weight during treatment with canagliflozin for type 2 diabetes mellitus [route not stated; not all times to reactions onset stated]. The woman was presented to the emergency department of Kanazawa Medical University Hospital, Uchinada, Japan. She had been suffering with type 2 diabetes mellitus from the last 20 years, and received treatment with antidiabetic medicines like repaglinide, vildagliptin and metformin beginning at the age of 40 years. She refused insulin therapy. She started receiving 100mg of canagliflozin on daily basis, 3 weeks prior to the hospitalisation. Three days prior to her admission, she experienced loss of appetite, epigastric pain and nausea. Hence, she consulted her family physician, and received a drip infusion of sodium chloride [saline] with vitamin B1 for 3 days. However, her symptoms became severe and she was brought to the emergency department. In hospital, her urine ketone body was 3+, but the blood glucose level was high, and an acute metabolic abnormality was suggested. She was admitted to the hospital. She reported that after the initiation of canagliflozin, she experienced 10kg of body weight loss over 3 weeks. She underwent abdominal ultrasonography, which revealed the diameter of the inferior vena cava was 8mm, without any respiratory variability and dehydration also noticed. Based on laboratory test, she was suspected of ketoacidosis with compensative respiratory alkalosis. A diagnosis of euglycemic ketoacidosis was made later. The woman’s canagliflozin therapy was discontinued. She started treatment with insulin, sodium chloride and glucose solution. Her therapy with metformin, vildagliptin and repaglinide were discontinued. A contrast CT showed SMA syndrome. To release the stomach fullness a nasogastric tube was inserted for 2 days. Three days after admission, her urinary ketone bodies disappeared, and abdominal symptoms improved. She started receiving insulin intensive therapy. Two weeks after hospitalisation, she was discharged on insulin therapy. During the follow up after 28 weeks of discharge, she gained an additional 7kg. Hirai T, et al. Case report of superior mesenteric artery syndrome that developed in a lean type 2 diabetes patient and was associated with rapid body weight loss after sodiumglucose cotransporter 2 inhibitor administration. Journal of Diabetes Investigation 11: 1359-1362, No. 5, Sep 2020. Available from: URL: http://doi.org/10.1111/ 803515829 jdi.13228
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
